Mizuho raised the firm’s price target on Guardant Health (GH) to $70 from $65 and keeps an Outperform rating on the shares following the investor day. The firm thinks the stock had a negative reaction due to the guide-down in implied volumes. However, it views the U.S. Preventive Services Task Force guideline delay as an expected headwind, and now sees the Shield ramp as “believable.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health’s Strong Growth Trajectory and Unique Oncology Approach Earns Buy Rating
- Wolfe upgrades Guardant to Outperform after ‘solid’ analyst day
- Guardant Health price target raised to $70 from $60 at JPMorgan
- Guardant Health upgraded to Outperform from Peer Perform at Wolfe Research
- Guardant Health price target raised to $80 from $70 at UBS